Primary Topics of Discussion
- Most efficient regulatory approval process for FIH trials – DOs & DONTs.
- Nitty Gritty; sample management and logistics to and from Australia.
- 43.5% R&D cash back: can be applicable to your entire IND-enabling GLP Toxicology package.
- Human Research Ethics Committee (HREC) requirements on nonclinical data.
- How Australia’s world class nonclinical through clinical research infrastructure supports early phase clinical research studies with speed, quality, and cost advantages.
- Holly Stefl – Chief Commercial Officer; Agilex Biolabs
- Dr. Bruce Morimoto – VP, Drug Development; Alto Neuroscience
- Jane Kelly – CEO; CMAX Clinical Research
- Dr. Alfred Botchway – CEO; Attentive Science
- Dr. Kurt Sales – Chief Scientific Officer; Agilex Biolabs
- Rima Darwiche – CEO; Central Pharmacy Logistics
- Rob Pluske – BD Executive; Linear Clinical Research
- Stewart Walker – President and Director; Acclime USA